1. DOP004 Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY. (16th January 2018) Authors: Bossuyt, P; Atreya, R; Taxonera, C; Hebuterne, X; Isaacs, K; Higgins, P D; Lindsay, J; Heap, G; Arikan, D; Kuehnl, V; Petersson, J; Robinson, A M; Loftus, E V Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S032 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn's disease: interim results of the CAPE registry. (16th January 2018) Authors: Turner, D; Koletzko, S; Winter, H; Baldassano, R; Dubinsky, M; Faubion, W; Hyams, J; Kugathasan, S; Rosh, J; Escher, J; Griffiths, A; Kierkus, J; Russell, R; Heap, G; Arikan, D; Kuehnl, V; Petersson, J; Robinson, A; Ruemmele, F Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S035 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗